Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N8-GP prophylaxis and treatment in previously treated Chinese patients with haemophilia A
2020-003001-58Phase 3
- Sponsor
- Novo Nordisk
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of octocog alfa in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Number of bleeding episodes.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2020-003001-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003001-58.